Long-term donor-specific tolerance in rat cardiac allografts by intrabone marrow injection of donor bone marrow cells

Transplantation
Kequan GuoS Ikehara

Abstract

Donor-specific central tolerance in cardiac allograft can be induced by hematopoietic chimerism via conventional intravenous bone marrow transplantation (IV-BMT). However, there are problems with IV-BMT, such as the risk of graft failure and of the toxicity from conditioning regimens. A new method for heart transplantation is presented. This method consists of administration of fludarabine phosphate (50 mg/kg) and fractionated low-dose irradiation (3.5 Gyx2 or 4.0 Gyx2), followed by intrabone marrow injection of whole bone marrow cells (IBM-BMT) plus heterotopic heart transplantation. Cardiac allografts with IBM-BMT were accepted and survived long-term (>10 months) showing neither acute rejection nor chronic rejection including cardiac allograft vasculopathy by such conditioning regimens. In contrast, cardiac allografts with conventional IV-BMT were rejected within 1 month after the treatment with irradiation of 3.5 Gyx2 or within 3 months after the treatment with irradiation of 4.0 Gyx2. Macrochimerism (>70%) was favorably established and stably maintained by IBM-BMT but not IV-BMT. Low levels of transient mixed chimerism (<7%) were induced by IV-BMT with fludarabine plus 4.0 Gyx2, but the chimerism was lost within 1 month aft...Continue Reading

References

Jun 27, 1992·Lancet·T E StarzlM Trucco
Jan 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H G ChunB D Cheson
Mar 3, 1994·The New England Journal of Medicine·H J SchlittR Pichlmayr
Apr 1, 1996·The Journal of Thoracic and Cardiovascular Surgery·S M PhamB P Griffith
Feb 25, 1999·Transplantation·C AsieduJ M Thomas
Apr 25, 2000·Annual Review of Medicine·M Weis, W von Scheidt
Aug 15, 2001·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·J D HosenpudR J Novick
May 21, 2003·Transplant International : Official Journal of the European Society for Organ Transplantation·Julian WallerMichael L Nicholson
Mar 12, 2004·Transplantation Proceedings·A P Monaco
Jun 15, 2004·Transplantation Proceedings·L V de MoraesL V Rizzo
Sep 7, 2005·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Hiroyuki KanedaSusumu Ikehara

❮ Previous
Next ❯

Citations

Jul 18, 2009·Clinical Reviews in Allergy & Immunology·Susumu Ikehara
Jun 10, 2008·Stem Cells and Development·Satoshi OkazakiSusumu Ikehara
Dec 18, 2009·Expert Review of Molecular Diagnostics·Josep-Maria Pujal
Sep 17, 2015·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Chen ChenShuzhong Guo
Sep 18, 2009·Annals of the New York Academy of Sciences·Susumu Ikehara
Nov 5, 2014·Frontiers in Cell and Developmental Biology·Kequan GuoXu Meng
Nov 5, 2014·Frontiers in Cell and Developmental Biology·Ming LiSusumu Ikehara
Nov 7, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sandra LangeChristian Junghanss

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.